Conversations in Drug Development Trends

DECEMBER 20, 2023

You can learn more about biomarkers and how to use them in oncology studies in this white paper. Single-Arm Trial Design Single-arm trials have also become an increasingly common development strategy to support regulatory approval and allow patients expedited access to novel therapies, particularly in the accelerated access setting.

Clinical Trials 83

Clinical Trials Trials Pharmacokinetics FDA 83

PPD

OCTOBER 2, 2024

A recent white paper from the PPD™ clinical research business of Thermo Fisher Scientific details how these functions have evolved over the years, moving from capabilities that were previously built up and maintained in-house, to the multiple outsourcing models available today.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Research Trials 52

Conversations in Drug Development Trends

JULY 29, 2024

However, the complex nature of T2D requires a multidimensional treatment approach that extends beyond drug therapy. Gene therapy, immunology, and CGM innovations provide new treatment possibilities. Research suggests that a combination of drugs and devices is most effective for managing T2D.

Clinical Research 52

Clinical Research Research Clinical Trials Treatment 52

The Pharma Data

OCTOBER 16, 2020

Paula Brown Stafford, chairman and CEO of Novan, said: “Covid-19 continues to have a major ongoing impact on global health and there remains a direct need for a safe and effective antiviral therapy. Download Medidata’s white paper to learn how to virtualize clinical trials and bring new therapies closer to patients.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

PPD

JUNE 17, 2024

Often, however, a hybrid use case will fit into one of these general categories: 1) An existing FSO arrangement needs additional expertise or resources to support a specific study function, requiring the developer to scale or augment that FSO arrangement with FSP services.

Clinical Trials 52

Clinical Trials Clinical Development Trials International 52

The Pharma Data

DECEMBER 28, 2020

Scopus is a biopharmaceutical company whose lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. Dr. Russell has managed all aspects of the drug development and regulatory approval processes for oncology and non-oncology drug candidates. David Weild IV.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Government Therapies 52

Alta Sciences

OCTOBER 28, 2024

White Paper: Whole Genome Sequencing, Proteomics, and Function Characterization of the Sinclair Nanopig™ Discover how the Sinclair Nanopig™ is transforming nonclinical safety assessments. Read the white paper. Issue 41 of The Altascientist focuses on bioanalytical testing for immunomodulatory drugs. Watch it now.

Science 52

Science Clinical Trials Trials FDA 52

Conversations in Drug Development Trends

APRIL 7, 2025

This approach improves treatment outcomes over traditional broad-spectrum therapies, which are prone to more side effects and adverse events. Carefully crafted enrichment strategies optimize recruitment and enrollment, ensuring that the included participants will likely respond to the therapy.

Research 40

Research Clinical Trials Trials Clinical Research 40

LifeSciVC

MARCH 12, 2025

This circumventing the wheel requires navigating around the roadblocks that hampered earlier drug development efforts to bring new treatment options forward for patients. ADCs are treatments comprised of three components: a drug payload joined by a linker to an antibody. ADCs are here to stay.

FDA Approval 52

FDA Approval Disease FDA Science 52